Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$602.00K$602.00Kderived+46.1% vs Q4 2022 Net Income-$1.03M-$1.03MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$321,000+186.6% Operating Incomederived-$1,024,000N/M Operating Cash Flowderived-$744,000N/M Free Cash Flowderived-$701,000N/M Margins · derivedGross margin53.3%+26.1 pt vs Q4 2022
Operating margin-170.1%+128.4 pt vs Q4 2022
Net margin-171.4%+127.8 pt vs Q4 2022
ended Jul 31, 2023 · filed Oct 30, 2023 · 91 d after period end